Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cloak And Dagger: GMP "Intelligence" Sought As Part Of Globalization Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency wants to target supply-chain threats and help judge the value of information received from third-party inspections.
Advertisement

Related Content

Drug Shortage Rules Surface In Latest FDA Regulatory Agenda
IOM Pushes For FDA Collaboration With Foreign Regulators
FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains
ANDA User Fees: Negotiators Close To Agreement, But Backlog Is Sticking Point
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
Generic User Fees Would Create 10-Month ANDA Review Time
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
FDA Globalization Efforts Gain Traction Even As Budget Request Emphasizes Old Inspection Model
FDA Globalization Efforts Gain Traction Even As Budget Request Emphasizes Old Inspection Model
FDA Overseas Staff Lacks Coordination With Agency's Centers, GAO Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS071955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel